GENI Earnings

GENI reported its FY2025Q4 earnings on 2026-03-04, showcasing a revenue of against an estimate of 235.52M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.02 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GENI's FY2025Q4 earnings announcement on 2026-03-04, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GENI's stock price tends to shift by an average of 0.29% in the 10 days leading up to earnings and -1.91% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate GENI's annual revenue to reach 227.03M, while the EPS is projected at 0.03. These estimates reflect recent revisions, with revenue estimates revised upward by 0.01% and EPS estimates revised upward by 0.01% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GENI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.01%, while EPS estimates moved revised upward by 0.01%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GENI's stock price typically moves by 0.29% in the 10 days before its earnings and -1.91% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.03 and revenue of 227.03M.

The earnings call summary and Q&A indicate several positive developments, including raised full-year guidance, strong media and betting revenue growth, and margin expansion. The NFL partnership extension and exclusive European soccer rights are strategic wins. Analysts' questions reveal optimism, with management addressing potential risks effectively. The company's focus on high-margin products and successful ad inventory creation further support a positive outlook. The market cap suggests moderate volatility, aligning with a 2-8% stock price increase prediction.